PATH Malaria Vaccine Initiative (MVI)

PATH Malaria Vaccine Initiative (MVI)

Consultation date: 07 August 2015

Malaria elimination strategy

MVI is one of the 3 initiatives that the Program for Appropriate Technology in Health (PATH) has to address global challenges in malaria.

MVI's research and development (R&D) strategy supports the long-term goal of eradicating malaria. The strategy aims to build on the success of GlaxoSmithKline Biologicals' RTS,S vaccine candidate that is now in the final stage of development in seven African countries. The strategy also includes approaches that seek to block malaria transmission and approaches that use weakened, whole parasites to protect against the disease.

MVI's R&D projects largely focus on Plasmodium falciparum, the most destructive malaria parasite that is found mainly in Africa. However, to further support efforts to eradicate malaria, MVI is increasing its focus on Plasmodium vivax, which causes a less severe—but more widespread—form of malaria. MVI's P. vivax program may yield candidates suitable for use in combination with those targeting P. falciparum.

Most new projects come to MVI as preclinical feasibility studies, with only a limited number advancing to full portfolio programs on a clinical track. This approach is an effective way to replenish MVI's portfolio and to maximize the program's potential for success.

In addition to providing direct support for vaccine development, MVI also invests in evaluation technologies to assess the potential efficacy of vaccine components. This is a critical component of MVI's R&D strategy and one that under-girds all vaccine development projects. MVI is also engaged in the process of defining acceptable vaccine product characteristics by developing target product profiles for each vaccine candidate and for potential candidates.

 

Funding 9 project(s)

CSV

Partnering on 41 project(s)

Mar 2011 to Dec 2013

Epidemiology Study of Malaria Transmission Intensity in Africa

Mar 2009 to Jan 2014

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

2005 to 2014

RTS,S/AS01 pediatric indication

CSV